Factors associated with nonreceipt of chemotherapy among patients with PCNSL who survived at least 3 months from diagnosis (N = 7068)
| Variable . | % not receiving chemotherapy . | Adjusted RR . | 95% CI . | P . |
|---|---|---|---|---|
| Age group, y | ||||
| 18-50 | 10.9 | Reference | <.0001 | |
| 51-60 | 10.1 | 0.96 | 0.77-1.21 | |
| 61-70 | 14.4 | 1.29 | 1.04-1.60 | |
| 71-80 | 23.3 | 2.01 | 1.60-2.54 | |
| >80 | 44.1 | 3.81 | 3.00-4.84 | |
| Sex | ||||
| Male | 16.7 | Reference | .98 | |
| Female | 18.1 | 1.00 | 0.91-1.10 | |
| Race | ||||
| White | 17.3 | Reference | <.0001 | |
| Black | 23.2 | 1.61 | 1.31-1.96 | |
| Asian/other | 14.1 | 1.00 | 0.77-1.31 | |
| Comorbidity index | ||||
| 0 | 15.8 | Reference | .0001 | |
| 1 | 19.2 | 1.07 | 0.95-1.21 | |
| ≥2 | 24.3 | 1.34 | 1.17-1.53 | |
| Prior malignancy | ||||
| No | 16.9 | Reference | .86 | |
| Yes | 20.7 | 1.01 | 0.89-1.15 | |
| Health insurance | ||||
| Private insurance | 10.9 | Reference | .0005 | |
| Not insured | 18.9 | 1.68 | 1.27-2.22 | |
| Medicaid | 15.7 | 1.43 | 1.12-1.82 | |
| Medicare | 22.9 | 1.22 | 1.04-1.42 | |
| Other | 17.6 | 1.29 | 0.81-2.05 | |
| Median income* | ||||
| <$30 000 | 19.8 | Reference | .06 | |
| $30 000-$35 999 | 18.3 | 0.93 | 0.79-1.09 | |
| $36 000-$45 999 | 17.7 | 0.88 | 0.76-1.03 | |
| ≥$46 000 | 15.5 | 0.82 | 0.70-0.95 | |
| Histology | ||||
| DLBCL | 15.9 | Reference | <.0001 | |
| PCNSL, NOS | 24.7 | 1.52 | 1.36-1.70 | |
| Anatomical location | ||||
| Brain | 17.9 | Reference | .013 | |
| Spinal cord | 15.8 | 0.79 | 0.63-0.99 | |
| Unspecified | 15.0 | 0.82 | 0.70-0.97 | |
| Type of cancer program | ||||
| Community | 21.1 | Reference | <.0001 | |
| Academic/research | 14.0 | 0.69 | 0.62-0.76 |
| Variable . | % not receiving chemotherapy . | Adjusted RR . | 95% CI . | P . |
|---|---|---|---|---|
| Age group, y | ||||
| 18-50 | 10.9 | Reference | <.0001 | |
| 51-60 | 10.1 | 0.96 | 0.77-1.21 | |
| 61-70 | 14.4 | 1.29 | 1.04-1.60 | |
| 71-80 | 23.3 | 2.01 | 1.60-2.54 | |
| >80 | 44.1 | 3.81 | 3.00-4.84 | |
| Sex | ||||
| Male | 16.7 | Reference | .98 | |
| Female | 18.1 | 1.00 | 0.91-1.10 | |
| Race | ||||
| White | 17.3 | Reference | <.0001 | |
| Black | 23.2 | 1.61 | 1.31-1.96 | |
| Asian/other | 14.1 | 1.00 | 0.77-1.31 | |
| Comorbidity index | ||||
| 0 | 15.8 | Reference | .0001 | |
| 1 | 19.2 | 1.07 | 0.95-1.21 | |
| ≥2 | 24.3 | 1.34 | 1.17-1.53 | |
| Prior malignancy | ||||
| No | 16.9 | Reference | .86 | |
| Yes | 20.7 | 1.01 | 0.89-1.15 | |
| Health insurance | ||||
| Private insurance | 10.9 | Reference | .0005 | |
| Not insured | 18.9 | 1.68 | 1.27-2.22 | |
| Medicaid | 15.7 | 1.43 | 1.12-1.82 | |
| Medicare | 22.9 | 1.22 | 1.04-1.42 | |
| Other | 17.6 | 1.29 | 0.81-2.05 | |
| Median income* | ||||
| <$30 000 | 19.8 | Reference | .06 | |
| $30 000-$35 999 | 18.3 | 0.93 | 0.79-1.09 | |
| $36 000-$45 999 | 17.7 | 0.88 | 0.76-1.03 | |
| ≥$46 000 | 15.5 | 0.82 | 0.70-0.95 | |
| Histology | ||||
| DLBCL | 15.9 | Reference | <.0001 | |
| PCNSL, NOS | 24.7 | 1.52 | 1.36-1.70 | |
| Anatomical location | ||||
| Brain | 17.9 | Reference | .013 | |
| Spinal cord | 15.8 | 0.79 | 0.63-0.99 | |
| Unspecified | 15.0 | 0.82 | 0.70-0.97 | |
| Type of cancer program | ||||
| Community | 21.1 | Reference | <.0001 | |
| Academic/research | 14.0 | 0.69 | 0.62-0.76 |
NOS, not otherwise specified.
In the patient’s zip code of residence, according to the 2012 American Community Survey data and grouped into population quartiles.